PolarityBio

PolarityBio is a US-based biotech focused on developing SkinTE®, an autologous, multicellular skin construct for regenerating functional tissue in chronic wounds like diabetic foot ulcers. The company's core technology involves harvesting a patient's healthy skin and processing it into 'organoid-like' structures containing cells and extracellular matrix components, which are then applied to the wound bed to seed healing. With its lead program in a pivotal Phase III trial and an FDA-cleared Expanded Access Program, PolarityBio is positioned in the high-need chronic wound market, though it remains pre-revenue and reliant on clinical and regulatory success for its investigational product.

Autologous regenerative skin platform that harvests a patient's healthy skin and manufactures it into 'organoid-like,' multicellular structures containing full cellular and extracellular matrix components to seed and initiate healing in chronic wounds.

PolarityBio competes in the advanced wound care market against other cellular and tissue-based products (e.g., Organogenesis's Apligraf, Smith & Nephew's Dermagraft), acellular matrices, and growth factors. SkinTE's autologous, multicellular composition aims to differentiate it as a more comprehensive regenerative therapy.